Compare VEEE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEE | CANF |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.5M |
| IPO Year | 2021 | N/A |
| Metric | VEEE | CANF |
|---|---|---|
| Price | $1.72 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 244.0K | ★ 567.7K |
| Earning Date | 11-06-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,680,921.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $3.36 |
| 52 Week High | $9.30 | $46.60 |
| Indicator | VEEE | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 76.89 |
| Support Level | $1.22 | $3.87 |
| Resistance Level | $1.72 | $4.43 |
| Average True Range (ATR) | 0.20 | 0.40 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 61.82 | 67.26 |
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.